Story thread · 2 reports / 2 sources
Claris collects $118M to take eye drop into pivotal testing next year
endpts.com · 14d
How the coverage leans
Across 2 sources · syndicated copies counted once
Claris Bio has a fresh CEO, new board chair and $118 million for two pivotal trials to see if its eye drop can succeed in a blinding disease with no pharmaceutical treatment options. It's a ...
First report: An eye drug biotech banks $118M and stocks its executive suite — biopharmadive.com, 14d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.